Compare · ENSC vs NVO
ENSC vs NVO
Side-by-side comparison of Ensysce Biosciences Inc. (ENSC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENSC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 50759.9x ENSC ($3.9M).
- Over the past year, ENSC is down 88.2% and NVO is down 45.1% - NVO leads by 43.1 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for ENSC).
- NVO has more recent analyst coverage (25 ratings vs 1 for ENSC).
- Company
- Ensysce Biosciences Inc.
- Novo Nordisk A/S
- Price
- $0.25-3.36%
- $43.88-0.20%
- Market cap
- $3.9M
- $195.92B
- 1M return
- -11.76%
- -6.80%
- 1Y return
- -88.18%
- -45.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 8
- Recent ratings
- 1
- 25
Ensysce Biosciences Inc.
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is headquartered in La Jolla, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ENSC
- SEC Form S-3 filed by Ensysce Biosciences Inc.
- Ensysce Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Ensysce Biosciences Reports First Quarter 2026 Financial Results
- Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
- Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
- SEC Form S-8 filed by Ensysce Biosciences Inc.
- Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
- SEC Form EFFECT filed by Ensysce Biosciences Inc.
- SEC Form S-3 filed by Ensysce Biosciences Inc.
- Ensysce Biosciences Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care